high-quality new

High-Quality New (Beijing) Medical Technology, commonly known as HQ New, is a Beijing-based biotechnology company and contract research organization (CRO) specializing in the discovery and development of innovative small molecule therapeutics. The company leverages its proprietary drug discovery platform to target high-value pathways in oncology and immunology, with a focus on oral small molecule inhibitors of immune checkpoints and innate immunity modulators. Its lead candidate, HQ-001, is a novel small molecule PD-L1 inhibitor currently undergoing clinical evaluation. HQ New provides a range of R&D services while advancing its internal pipeline of candidates targeting PD-L1, STING, and other key biological targets.